A pharmacogenetics-based pharmacokinetic model explains the difference in harmaline drug effects between wild-type and CYP2D6-humanized mouse models

被引：0
|
作者：
Jiang, Xiling [1 ]
Wu, Chao [1 ]
Shen, Hongwu [2 ]
Yu, Ai-Ming
机构：
[1] SUNY Buffalo, Dept Pharmaceut Sci, Sch Pharm & Pharmaceut Sci, Amherst, NY 14260 USA
[2] SUNY Buffalo, Dept Pharmaceut Sci, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14260 USA
来源：
DRUG METABOLISM REVIEWS | 2009年 / 41卷
关键词：
BETA-CARBOLINE ALKALOIDS; CYTOCHROME-P450; MICE;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
337
引用
收藏
页码：167 / 168
页数：2
相关论文
共 18 条
  • [1] Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model
    Wu, Chao
    Jiang, Xi-Ling
    Shen, Hong-Wu
    Yu, Ai-Ming
    [J]. BIOCHEMICAL PHARMACOLOGY, 2009, 78 (06) : 617 - 624
  • [2] Sex steroid hormones differentially regulate CYP2D in female wild-type and CYP2D6-humanized mice
    Konstandi, Maria
    Andriopoulou, Christina E.
    Cheng, Jie
    Gonzalez, Frank J.
    [J]. JOURNAL OF ENDOCRINOLOGY, 2020, 245 (02) : 301 - 314
  • [3] Stimulus control by 5-methoxy-N,N-dimethyltryptamine in wild-type and CYP2D6-humanized mice
    Winter, J. C.
    Amorosi, D. J.
    Rice, Kenner C.
    Cheng, Kejun
    Yu, Ai-Ming
    [J]. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2011, 99 (03) : 311 - 315
  • [4] CYP2D6-HUMANIZED MICE AS A MODEL TO STUDY ALTERED DRUG METABOLISM DURING PREGNANCY
    Jeong, Hyun-Young
    [J]. DRUG METABOLISM AND PHARMACOKINETICS, 2017, 32 (01) : S7 - S7
  • [5] Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses
    Tolledo, Edgor Cole
    Miksys, Sharon
    Gonzalez, Frank J.
    Tyndale, Rachel F.
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (03) : 701 - 712
  • [6] Effects of 3,3′-Dichlorobiphenyl (PCB-11) on the expression of CYP2A, 2B, and 2F enzymes in the liver and brain of CYP2A6-humanized, CYP2B6-humanized, or wild-type mice
    Han, Weiguo
    Yang, Weizhu
    Li, Xueshu
    Hans-Joachim, Lehmler
    Zhang, Qing-Yu
    Lein, Pamela
    Ding, Xinxin
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2023, 385
  • [7] Physiologically Based Pharmacokinetic Model Verification and Improvement for CYP2D6-mediated Drug-drug Interaction Prediction
    Ning, Miaoran
    Posada, Maria M.
    Hall, Stephen D.
    Dickinson, Gemma L.
    [J]. FASEB JOURNAL, 2017, 31
  • [8] EVALUATION OF A PXR-CAR-CYP3A4/3A7-CYP2D6-CYP2C9 MULTIPLE HUMANIZED MOUSE MODEL TO PREDICT DRUG-DRUG INTERACTIONS IN MAN
    Scheer, Nico
    Kapelyukh, Yury
    McLaughlin, Lesley A.
    McMahon, Mike
    Rode, Anja
    Henderson, Colin J.
    Wolf, C. Roland
    [J]. DRUG METABOLISM REVIEWS, 2015, 47 : 81 - 82
  • [9] Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions
    Huang, Weize
    Nakano, Mariko
    Sager, Jennifer
    Ragueneau-Majlessi, Isabelle
    Isoherranen, Nina
    [J]. DRUG METABOLISM AND DISPOSITION, 2017, 45 (11) : 1156 - 1165
  • [10] Physiologically-Based Pharmacokinetic Models of CYP2D6 Substrate and Inhibitors Nebivolol, Cinacalcet and Mirabegron to Simulate Drug–Drug Interactions
    Peter Kilford
    Nika Khoshaein
    Roz Southall
    Iain Gardner
    [J]. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47 : 699 - 710
12